First FDA-approved 3-D manufactured drug hits the market

The first FDA-approved drug produced using 3-D printing is now on the market. Aprecia Pharmaceuticals said this week that it has launched its epilepsy drug, Spritam, that is manufactured through three-dimensional printing technology. Spritam is a formulation of levetiracetam that uses the process so the pills rapidly disintegrate with a sip of liquid, making them easier to swallow. Aprecia has two facilities for manufacturing, one in Blue Ash, OH, where the company is headquartered, and one in East Windsor, NJ. A spokesperson said the company is currently investing $25 million in its 190,000-square-foot Blue Ash manufacturing facility. Release

Suggested Articles

Pfizer is scaling up an ambitious supply chain and distribution system aimed at delivering hundreds of millions of COVID vaccines around the world.

The FDA cited Arizona's RLC Labs for failing to ensure potency for two thyroid meds that were the subject of a recall in September.

The FDA is reportedly mulling a warning letter for an Eli Lilly site where its COVID-19 antibody would be produced.